IP Library › Granted Patent US 9,073,871
Granted Patent B2
US 9,073,871 · App. 14/471,576 · Granted Jul 7, 2015

Glucagon receptor modulators

Inventors: Gary Erik Aspnes (Rockville, RI); Mary Theresa Didiuk (Madison, CT); Kevin James Filipski (Reading, MA); Angel Guzman-Perez (Belmont, MA); Esther Cheng Yin Lee (Brookline, MA); Jeffrey Allen Pfefferkorn (Acton, MA); Benjamin Dawson Stevens (Cambridge, MA); Meihua Mike Tu (Acton, MA)
Assignee: Pfizer Inc.
C07D231/12C07D207/34C07D231/14C07D231/16C07D231/18C07D231/54C07D231/56C07D233/61C07D233/64C07D233/68C07D233/70C07D233/84C07D249/06C07D249/08C07D261/08C07D401/04C07D401/12C07D401/14C07D403/04C07D405/14C07D487/04C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,073,871
App. No.
14/471,576
Granted
Jul 7, 2015
Kind
B2
Abstract

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 , A 1 , A 2 , A 3 , A 4 , L, B 1 , B 2 , B 3 and B 4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Claims (3)

1. A compound of structure

2. A compound of structure

or a pharmaceutically acceptable salt thereof.

Continuity (6)
Continuation 13934322 · Jul 3, 2013
Continuation 13367459 · Feb 7, 2012
Provisional Application 61585834 · Jan 12, 2012
Provisional Application 61441044 · Feb 9, 2011
Provisional Application 61440578 · Feb 8, 2011
Related Publication 20140371467A1 · Dec 18, 2014